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Looking for Unique Signatures in a Heterogeneous Syndrome*Thomas J. Wang, MD, Deepak K. Gupta, MDSEE PAGE 1509H eart failure (HF) is a leading cause of mor-bidity and mortality, particularly amongthe elderly (1). Despite established criteria
for HF, substantial interindividual variation in symp-
toms and signs may cloud the clinical diagnosis (2).
Circulating biomarkers, such as natriuretic peptides,
may aid in diagnosis; however, HF is a heterogeneous
syndrome, and consequently, no single noninvasive
test provides 100% accuracy in deﬁning the HF status
of a symptomatic patient (3). Once diagnosed,
etiological considerations include ischemic and noni-
schemic causes (e.g., hypertensive, valvular, genetic
cardiomyopathies, metabolic, inﬁltrative, toxins, infec-
tious, arrhythmic, and pericardial). Although HF is
characterized by acute decompensations, recurrent
hospitalizations, and increased mortality, prognosis
varies according to etiology, comorbidities, and func-
tional impairment. Consequently, there is consider-
able interest in identifying novel biomarkers that
not only may improve diagnosis, but that also
enhance prognostication, guide individual therapy,
or inform pathophysiological understanding of the
HF syndrome (4).
Increasing evidence suggests HF is associated
with metabolic dysfunction (5). Insulin resistance,
diabetes mellitus, and obesity are risk factors for HF
development. In patients with HF, myocardial sub-
strate utilization largely switches from using fatty*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Vanderbilt Translational and Clinical Cardiovascular Research
Center and Division of Cardiovascular Medicine, Vanderbilt University
Medical Center, Nashville, Tennessee. Dr. Wang is named as a co-
inventor on patent applications on metabolomic and neurohormonal
biomarkers of cardiometabolic disease; has received grant or assay sup-
port from Diasorin, Critical Diagnostics, LabCorp, Siemens, Singulex, and
Brahms; and has served on advisory committees with Diasorin and
Critical Diagnostics. Dr. Gupta has reported that he has no relationships
relevant to the contents of this paper to disclose.acids to using glucose (6,7). Therefore, determining
circulating metabolite proﬁles that are characteristic
of HF is an attractive approach to discover valuable
biomarkers. Recent advances inmolecular techniques,
computing power, and bio-informatics have enabled
efﬁcient metabolite proﬁling on a larger scale (8).In this issue of the Journal, Cheng et al. (9) present
their evaluation of the diagnostic and prognostic
values of circulating metabolites in HF. In the dis-
covery phase, untargeted mass spectrometry found
that the metabolic proﬁles of American College of
Cardiology/American Heart Association (ACC/AHA)
stage C HF patients (n ¼ 68) were considerably dif-
ferent from those of healthy control subjects (n ¼ 51).
Speciﬁc metabolites that differed between these
2 groups were then studied in targeted analyses, again
initially comparing stage C HF patients with healthy
subjects, which conﬁrmed that the metabolic proﬁles
varied between these 2 groups. A validation study of
218 stage C HF patients and 63 healthy control sub-
jects replicated these results. Additional discovery
phase analyses included ACC/AHA stage A (n ¼ 43)
and B (n ¼ 67) patients, and as might be expected,
because of the progressive nature of HF, their
metabolic proﬁles spanned the distribution between
healthy subjects and stage C patients.
Using receiver-operating curve (ROC) analysis,
the investigators identiﬁed a combination of 4
metabolites (histidine, phenylalanine, spermidine,
and phosphatidylcholine C34:4) that differentiated
stage C HF patients from healthy control subjects.
The discriminatory ability of this combination was
similar to that of B-type natriuretic peptide (BNP)
alone. However, the ROC analyses did not assess
clinical variables, such as age, comorbidities, and
medications, which likely would have had a high area
under the curve because of the stark contrast between
TABLE 1 Human Studies of Metabolomics in Heart Failure
First Author (Ref. #) Derivative Sample Validation Sample Specimen Technique Metabolic Proﬁle Diagnostic Prognostic p Value Threshold
Kang et al. (10) Ischemic HFrEF (n ¼ 15) vs.
age- and sex-matched healthy
(n ¼ 20)
HF (n ¼ 27) vs.
healthy
(n ¼ 29)
Urine 1H-NMR Higher: acetate, acetone, methylmalonic
acid, cytosine, phenylacetylglycine
Lower: 1-methylnicotinomide
Differentiates HF
from healthy
Not assessed <0.05
Samara et al. (11) ADHF (n ¼ 25) vs. CVD w/o
HF (n ¼ 16)
ADHF (n ¼ 36) Breath SIFT-MS Higher: acetone, pentane,
H30þ, O2þ, NOþ
Differentiates HF
from non-HF
Not assessed <0.05
Tenori et al. (14) Stable HF (n ¼ 185) vs. age- and
sex-matched healthy (n ¼ 111)
None Serum 1H-NMR Higher: phenylalanine, tyrosine, isoleucine,
creatine
Lower: lactate, citrate, lysine, L-3,4-dihydroxyphenylalanine
86% accuracy in
differentiating
HF from healthy
Not assessed Not reported
Wang et al. (15) Ischemic HF (n ¼ 39) vs.
age-matched healthy
(n ¼ 15)
None Plasma 1H-NMR Higher: lactate, alanine, creatine, proline,
isoleucine, leucine, LDL, VLDL
Lower: HDL, valine, glycoprotein, glutamine,
glutamate, unsaturated lipid, choline,
glycine, glucose, tyrosine, histidine
Differentiates HF
from healthy
Not assessed <0.05
Turer et al. (16) Cardiac surgery for CAD or LV
dysfunction (n ¼ 22) vs.
cardiac surgery w/o CAD or
LV dysfunction (n ¼ 17)
None Plasma MS Lower: myocardial glucose, fatty acid,
amino acid uptake
Differentiates LV
dysfunction from
non-LV dysfunction
Not assessed <0.05
Dunn et al. (17) HFrEF (n ¼ 52) vs. age-matched
no CVD (n ¼ 57)
None Serum GC-MS Higher: pseudouridine, 2-oxoglutarate Differentiates HF
from healthy
Not assessed <0.00005
Desmoulin et al. (12) ADHF (n ¼ 126) ADHF (n ¼ 74) Plasma 1H-NMR Higher risk: lactate
Lower risk: total cholesterol
Not assessed 30-day mortality
(lactate/chol
AUC ¼ 0.82)
<0.05
Zheng et al. (13) ARIC-Jackson (n ¼ 1,744) None Plasma GC & LC MS Higher risk: hydroxyleucine
Lower risk: dihydroxy docosatrienoic acid
Not assessed Incident HF <0.0004
1H-NMR ¼ proton nuclear magnetic resonance; ADHF ¼ acute decompensated heart failure; ARIC ¼ Atherosclerosis Risk in Communities; AUC ¼ area under the curve; CAD ¼ coronary artery disease; CVD ¼ cardiovascular disease; GC ¼ gas chromatography;
HDL ¼ high-density lipoprotein cholesterol; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; LC ¼ liquid chromatography; LDL ¼ low-density lipoprotein cholesterol; LV ¼ left ventricular; MS ¼ mass spectrometry; NO ¼ nitric oxide;
O2 ¼ oxygen; SIFT ¼ selected ion-ﬂow tube; VLDL ¼ very low-density lipoprotein cholesterol.
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1523stage C HF patients and healthy subjects. Although
the investigators performed multivariable-adjusted
analyses, several covariates were not included, such
as the presence of ischemic heart disease, body mass
index, blood pressure, glomerular ﬁltration rate,
glucose, lipids, and medications. Collectively, unac-
counted differences between patients and control
subjects likely reduced the speciﬁcity of the metab-
olite proﬁles for HF.
The investigators also evaluated the prognostic
value of a metabolomic proﬁle among 140 stage B
and C HF patients over a mean follow-up of 1.3 years,
during which time, 47 deaths or HF hospitalizations
occurred. Here, a different combination of 4 metab-
olite parameters (dimethylarginine/arginine ratio,
spermidine, butyrylcarnitine, and total essential
amino acids) was associated with the composite
outcome. In ROC analyses, this panel correctly clas-
siﬁed 85% of patients who developed an event versus
74% in whom BNP was used alone. This result was
conﬁrmed in the validation set.
Finally, Cheng et al. (9) performed a longitudinal
analysis in 32 stage C HF patients who demonstrated
“recovery” from acute decompensated HF to New
York Heart Association functional class I and survived
for 1 year. Levels of histidine, phenylalanine, sper-
midine, and phospatidylcholine C34:4, as well as
BNP, signiﬁcantly improved at 6 and 12 months
compared with the levels at the time of decom-
pensated HF, which supported the dynamic nature of
the plasma metabolome that changes according to HF
severity.
This study adds to the relatively few other studies
in the literature regarding metabolomics in HF
(Table 1) (10–17). The investigators examined a larger
number of patients than most previous studies,
included discovery and validation sets, and presented
a dynamic analysis of HF patients with temporal
improvement in functional status. In the discovery
phase, they also proﬁled ACC/AHA stage A and B pa-
tients, and showed that circulating metabolite pat-
terns shifted with progression to clinical symptomatic
HF. In the context of existing literature, this supports
the concept that HF is associated with metabolic
dysfunction.
However, the clinical utility of metabolite proﬁling
in HF remains uncertain, largely because discrimi-
nating symptomatic HF patients from healthy control
subjects is not representative of clinical practice.
Studies comparing the circulating metabolic proﬁle of
symptomatic patients with and without HF would be
more informative (3). In addition, novel metabolic
proﬁles must be rigorously tested against clinical
characteristics alone and with BNP (or N-terminalpro-BNP) to determine whether incremental diag-
nostic or prognostic value is gained.
HF is a syndrome characterized by the heart’s
inability to provide sufﬁcient blood ﬂow to support
the body’s metabolic needs at normal ﬁlling pressures.
Proﬁling plasma or serum reﬂects a partial snapshot of
the body’s global metabolic state in the setting of HF
without attribution to the speciﬁc organ affected. The
combination and pattern of circulating molecules re-
ﬂects the composite exchange of metabolites between
the circulation and organs or tissue, all of which may
be affected by medications, the patient’s nutritional
state, and environmental inﬂuences.
The handful of existing metabolomic studies in HF
has reported a diverse array of molecular proﬁles
(Table 1), perhaps reﬂecting the heterogeneous nature
of HF; consequently, there may be no uniform
metabolic signature. Moreover, existing studies pre-
dominantly examined patients with HF and reduced
ejection fraction, which only accounts for one-half
of all HF cases. HF with preserved ejection fraction is
itself a heterogeneous syndrome, which might be
associated with a range of metabolic abnormalities
(18). Therefore, metabolomic studies of broader HF
populations would likely yield variable results.
Other factors contributing to variation in study
results include differences in study design, assays
used, and statistical methodology. The number of
metabolites examined in each study also varies, as do
the thresholds for determining statistical signiﬁcance.
Metabolomic proﬁling in HF offers a promising
approach, with a foundation in biological plausibility.
The research presented by Cheng et al. (9) extends
the experience with metabolite proﬁling in HF and
illustrates the potential value of longitudinal data.
Nonetheless, as the investigators indicated, further
studies are needed to understand the clinical utility
of characterizing metabolite proﬁles in HF. Because
HF is a heterogeneous syndrome that includes sub-
populations of patients who differ by etiology,
comorbidities, and severity of illness, we need to
parse out unique phenotypes that may respond
differently to therapies or have different natural his-
tories. There is the hope that metabolomic proﬁling,
in combination with other “-omic” techniques, such
as genomics and proteomics, will eventually facilitate
identiﬁcation of these phenotypic signatures.
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